微针在术后早期瘢痕中的疗效
研究纳入25例术后瘢痕患者,在术后早期接受三次微创经皮胶原诱导(微针)治疗,于每次治疗后及末次治疗后2个月随访时用温哥华瘢痕量表、患者与观察者瘢痕评估量表及整体美学改善量表评估。治疗16周时各量表评分较初始测量均有改善(p < 0.001),术后6至7周开始治疗者在患者与观察者瘢痕评估量表上优于13至16周开始者(p < 0.04),未报告不良结局。
要点
- 术后瘢痕接受微针治疗16周时温哥华瘢痕量表等评分较初始改善(p < 0.001)。
- 术后6至7周开始微针治疗者患者与观察者瘢痕评估量表优于13至16周开始者(p < 0.04)。
- 微针治疗术后瘢痕未报告不良结局。
核心结论
- 在瘢痕成熟与重塑期对术后瘢痕行微创经皮胶原诱导治疗未出现不良结局。
- 数据表明在成熟期早期(术后6至7周)开始治疗者美学效果优于成熟期晚期(术后13至16周)开始者。
研究设计与样本
- 研究纳入25例接受手术的患者,术后对其瘢痕进行三次微创经皮胶原诱导治疗。
- 于三次治疗各自结束后及末次治疗后2个月随访时进行瘢痕评估。
主要发现
- 治疗开始后16周评估时,温哥华瘢痕量表、患者与观察者瘢痕评估量表及整体美学改善量表评分较初始测量均有改善(p < 0.001)。
- 比较患者年龄、瘢痕部位或Fitzpatrick光皮型时未发现统计学显著差异。
- 术后6至7周开始治疗者与术后13至16周开始治疗者在患者与观察者瘢痕评估量表上差异有统计学意义(p < 0.04)。
关键数值与推荐
- 温哥华瘢痕量表、患者与观察者瘢痕评估量表及整体美学改善量表评分在治疗开始后16周较初始测量改善(p < 0.001)。
- 术后6至7周开始治疗组与术后13至16周开始治疗组在患者与观察者瘢痕评估量表上差异有统计学意义(p < 0.04)。
临床怎么用
- 作者认为微创经皮胶原诱导可用于术后早期瘢痕,未报告不良结局。
- 作者认为在成熟期早期(术后6至7周)开始治疗可能获得更优美学效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Scars are a vexing sequela of surgery. Microneedling, also known as minimally invasive percutaneous collagen induction, has demonstrated impressive improvements in chronic acne scars; however, no evidence exists for treating postsurgical scars during active wound healing. The purpose of this study was to demonstrate the utility and safe use of minimally invasive percutaneous collagen induction in acute postsurgical scars. METHODS: Twenty-five patients who underwent surgery had scars treated with three treatments of minimally invasive percutaneous collagen induction in the postoperative period. Scar assessment was measured by Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, and Global Aesthetic Improvement Scale after each of the three treatments and at final 2-month follow-up. RESULTS: Patients had positive improvement in Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, and Global Aesthetic Improvement Scale scores at 16-week posttreatment initiation evaluation compared to initial measurement ( p < 0.001). No statistically significant differences were noted when comparing the age of the patient, location of scars, or Fitzpatrick phototype scales among patients. When comparing patients who began treatment early (6 to 7 weeks postoperatively) to those who began treatment late (13 to 16 weeks postoperatively), there was a statistically significant difference in the Patient and Observer Scar Assessment Scale group ( p < 0.04). CONCLUSIONS: Postsurgical scars treated with minimally invasive percutaneous collagen induction in the maturation and remodeling phase had no adverse outcomes. Interestingly, the data show treatment initiated early in the maturation phase (6 to 7 weeks postoperatively), while natural collagen formation was tapering off, demonstrated improved aesthetic outcomes compared to treatments initiated late in the maturation phase (13 to 16 weeks postoperatively). CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
引用
- Claytor RB, Sheck CG, Chopra V, et al. Microneedling Outcomes in Early Postsurgical Scars. Plast Reconstr Surg. 2022. PMID: 35759632. doi:10.1097/PRS.0000000000009466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。